Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Supportive Care Drugs Market

4. Market Overview
    4.1. Introduction
        4.1.1. Drug Class Definition
        4.1.2. Industry Evolution/ Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
        4.4.2. Market Volume/Unit Shipments Projections
    4.5. Porter’s Five Force Analysis

5. Key Insights
    5.1. Key Drug Class/Brand Analysis
    5.2. Top 3 Players Operating in the Market Space
    5.3. Disease Prevalence and Incidence
    5.4. COVID Impact Analysis

6. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Drug Class, 2017-2031
        6.3.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
        6.3.2. ESAs (Erythropoiesis Stimulating Agent)
        6.3.3. Antiemetics
        6.3.4. Bisphosphonates
        6.3.5. Opioids
        6.3.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
        6.3.7. Others (Topicals, etc.)
    6.4. Market Attractiveness By Drug Class

7. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Indication
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Indication, 2017-2031
        7.3.1. Lung Cancer
        7.3.2. Breast Cancer
        7.3.3. Prostate Cancer
        7.3.4. Liver Cancer
        7.3.5. Bladder Cancer
        7.3.6. Leukemia
        7.3.7. Others (Ovarian Cancer, Melanoma, etc.)
    7.4. Market Attractiveness By Indication

8. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast By Distribution Channel, 2017-2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Others (Compounding Pharmacies, etc.)
    8.4. Market Attractiveness By Distribution Channel

9. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Region
    9.1. Key Findings
    9.2. Market Value Forecast By Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness By Country/Region

10. North America Cancer Supportive Care Drugs Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast By Drug Class, 2017-2031
        10.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
        10.2.2. ESAs (Erythropoiesis Stimulating Agent)
        10.2.3. Antiemetics
        10.2.4. Bisphosphonates
        10.2.5. Opioids
        10.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
        10.2.7. Others (Topicals, etc.)
    10.3. Market Value Forecast By Indication, 2017-2031
        10.3.1. Lung Cancer
        10.3.2. Breast Cancer
        10.3.3. Prostate Cancer
        10.3.4. Liver Cancer
        10.3.5. Bladder Cancer
        10.3.6. Leukemia
        10.3.7. Others (Ovarian Cancer, Melanoma, etc.)
    10.4. Market Value Forecast By Distribution Channel, 2017-2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Others (Compounding Pharmacies, etc.)
    10.5. Market Value Forecast By Country, 2017-2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Class
        10.6.2. By Indication
        10.6.3. By Distribution Channel
        10.6.4. By Country

11. Europe Cancer Supportive Care Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast By Drug Class, 2017-2031
        11.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
        11.2.2. ESAs (Erythropoiesis Stimulating Agent)
        11.2.3. Antiemetics
        11.2.4. Bisphosphonates
        11.2.5. Opioids
        11.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
        11.2.7. Others (Topicals, etc.)
    11.3. Market Value Forecast By Indication, 2017-2031
        11.3.1. Lung Cancer
        11.3.2. Breast Cancer
        11.3.3. Prostate Cancer
        11.3.4. Liver Cancer
        11.3.5. Bladder Cancer
        11.3.6. Leukemia
        11.3.7. Others (Ovarian Cancer, Melanoma, etc.)
    11.4. Market Value Forecast By Distribution Channel, 2017-2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Others (Compounding Pharmacies, etc.)
    11.5. Market Value Forecast By Country, 2017-2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Class
        11.6.2. By Indication
        11.6.3. By Distribution Channel
        11.6.4. By Country
12. Asia Pacific Cancer Supportive Care Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Drug Class, 2017-2031
        12.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
        12.2.2. ESAs (Erythropoiesis Stimulating Agent)
        12.2.3. Antiemetics
        12.2.4. Bisphosphonates
        12.2.5. Opioids
        12.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
        12.2.7. Others (Topicals, etc.)
    12.3. Market Value Forecast By Indication, 2017-2031
        12.3.1. Lung Cancer
        12.3.2. Breast Cancer
        12.3.3. Prostate Cancer
        12.3.4. Liver Cancer
        12.3.5. Bladder Cancer
        12.3.6. Leukemia
        12.3.7. Others (Ovarian Cancer, Melanoma, etc.)
    12.4. Market Value Forecast By Distribution Channel, 2017-2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Others (Compounding Pharmacies, etc.)
    12.5. Market Value Forecast By Country, 2017-2031
        12.5.1. China
        12.5.2. India
        12.5.3. Japan
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Class
        12.6.2. By Indication
        12.6.3. By Distribution Channel
        12.6.4. By Country
13. Latin America Cancer Supportive Care Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast By Drug Class, 2017-2031
        13.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
        13.2.2. ESAs (Erythropoiesis Stimulating Agent)
        13.2.3. Antiemetics
        13.2.4. Bisphosphonates
        13.2.5. Opioids
        13.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
        13.2.7. Others (Topicals, etc.)
    13.3. Market Value Forecast By Indication, 2017-2031
        13.3.1. Lung Cancer
        13.3.2. Breast Cancer
        13.3.3. Prostate Cancer
        13.3.4. Liver Cancer
        13.3.5. Bladder Cancer
        13.3.6. Leukemia
        13.3.7. Others (Ovarian Cancer, Melanoma, etc.)
    13.4. Market Value Forecast By Distribution Channel, 2017-2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Others (Compounding Pharmacies, etc.)
    13.5. Market Value Forecast By Country, 2017-2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Class
        13.6.2. By Indication
        13.6.3. By Distribution Channel
        13.6.4. By Country
14. Middle East & Africa Cancer Supportive Care Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast By Drug Class, 2017-2031
        14.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
        14.2.2. ESAs (Erythropoiesis Stimulating Agent)
        14.2.3. Antiemetics
        14.2.4. Bisphosphonates
        14.2.5. Opioids
        14.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
        14.2.7. Others (Topicals, etc.)
    14.3. Market Value Forecast By Indication, 2017-2031
        14.3.1. Lung Cancer
        14.3.2. Breast Cancer
        14.3.3. Prostate Cancer
        14.3.4. Liver Cancer
        14.3.5. Bladder Cancer
        14.3.6. Leukemia
        14.3.7. Others (Ovarian Cancer, Melanoma, etc.)
    14.4. Market Value Forecast By Distribution Channel, 2017-2031
        14.4.1. Hospital Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Others (Compounding Pharmacies, etc.)
    14.5. Market Value Forecast By Country, 2017-2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Class
        14.6.2. By Indication
        14.6.3. By Distribution Channel
        14.6.4. By Country

15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of companies)
    15.2. Market Share Analysis By Company (2022)
    15.3. Company Profiles
        15.3.1. Amgen, Inc.
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Material Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Merck & Co., Inc.
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Material Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Johnson & Johnson Services, Inc.
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Material Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Heron Therapeutics, Inc.
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Material Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Novartis AG
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Material Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. GSK plc
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Material Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. F. Hoffmann-La Roche Ltd.
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Material Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. Helsinn Healthcare SA
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Material Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Cancer Supportive Care Drugs Market Size (US$ Mn) Forecast, 2017-2031

Figure 02: Global Cancer Supportive Care Drugs Market Value Share, by Drug Class (2022)

Figure 03: Global Cancer Supportive Care Drugs Market Value Share, by Indication (2022)

Figure 04: Global Cancer Supportive Care Drugs Market Value Share, by Distribution Channel (2022)

Figure 05: Global Cancer Supportive Care Drugs Market Value Share, by Region (2022)

Figure 06: Global Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031

Figure 07 Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031

Figure 08: Global Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031

Figure 09: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031

Figure 10: Global Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031

Figure 11: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 12: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 13: Global Cancer Supportive Care Drugs Market Value Share, by Region, 2017-2031

Figure 14: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Region, 2017-2031

Figure 15: North America Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031

Figure 16: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031

Figure 17: North America Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031

Figure 18: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031

Figure 19: North America Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031

Figure 20: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 21: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 22: North America Cancer Supportive Care Drugs Market Value Share, by Country, 2017-2031

Figure 23: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country, 2017-2031

Figure 24: Europe Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031

Figure 25: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031

Figure 26: Europe Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031

Figure 27: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031

Figure 28: Europe Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031

Figure 29: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 30: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 31: Europe Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031

Figure 32: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 33: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031

Figure 34: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031

Figure 35: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031

Figure 36: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031

Figure 37: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031

Figure 38: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 39: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 40: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031

Figure 41: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 42: Latin America Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031

Figure 43: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031

Figure 44: Latin America Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031

Figure 45: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031

Figure 46: Latin America Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031

Figure 47: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 48: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 45: Latin America Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031

Figure 50: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 51: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031

Figure 52: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031

Figure 53: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031

Figure 54: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031

Figure 55: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031

Figure 56: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 57: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 58: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031

Figure 59: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

List of Tables

List of Tables

Table 01: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 02: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 03: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 04: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 05: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 06: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 07: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 08: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 09: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 10: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 11: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 12: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 13: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 14: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 15: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 16: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 17: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 18: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 19: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 20: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 21: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 22: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 23: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 24: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031